CA
NZ
UK
AU
IND
US
Definium Therapeutics (NASDAQ:DFTX) was indicated up 5.24% in the October 9, 2026 premarket session on the screener, on a listed price of USD 34.18 and premarket volume of 2,978 shares. The screener lists no catalyst, and a search found no company announcement or filing …
Doximity (NYSE:DOCS) reported fiscal first-quarter revenue of USD 156.6 million, an increase of 7%, according to a secondary summary of the company release on October 8, 2026. Net income was USD 24.3 million, compared with USD 53.3 million a year earlier, a drop of …
Eikon Therapeutics (NASDAQ:EIKN) was indicated up 6.00% in the October 9, 2026 premarket session on the screener, on a listed price of USD 7.50 and premarket volume of only 100 shares. The screener lists no catalyst, and a search found no company announcement from …
Bayer said on October 8, 2026 that the FDA accepted its supplemental new drug application for Kerendia in non-diabetic chronic kidney disease. The application is based on the FIND-CKD trial. A supplemental application seeks to expand the approved use of a drug already on …
AngioDynamics (NASDAQ:ANGO) announced on October 8, 2026 that Eric Honroth will succeed retiring chief executive Jim Clemmer, who leaves the board on November 2. The announcement came with quarterly results in a company release and an 8-K filing. The topics file does not describe …
Pfizer (NYSE:PFE) said the FDA approved Tukysa, known generically as tucatinib, for first-line maintenance treatment in HER2-positive breast cancer. The supporting figure is progression-free survival of 24.9 months versus 16.3 months for the comparison group. Progression-free survival measures how long patients live without their …
argenx (NASDAQ:ARGX) said it is discontinuing a late-stage trial of efgartigimod in Sjogren's disease because the study did not show enough efficacy, according to a company announcement reported on October 8, 2026. The shares fell, but the file does not give the size of …
Atrium Therapeutics (NASDAQ:RNA) was indicated down 3.15% in the October 9, 2026 premarket session on the screener, on a listed price of USD 8.26. The cause is a company announcement dated October 8, 2026 of a privatePlacementwith expected gross proceeds of about USD 50 …
Bristol Myers Squibb (NYSE:BMY) said a Phase 3 trial of Zenbexus showed a 51% cut in the risk of disease progression in multiple myeloma, a cancer of plasma cells in the bone marrow, according to a company release reported on October 8, 2026. The …
Clover Health (NASDAQ:CLOV) was indicated up 11.35% in the October 9, 2026 premarket session on the screener, on a listed price of USD 4.58 and premarketVolumeof 40,045 shares. The screener tags the catalyst as news, but a search found no company release, filing or …
Please wait processing your request...